In line with Sheba’s commitment to providing ‘hope without boundaries,’ improving care, and supporting its patients in combating even the most complex conditions, we are always on the lookout for impactful collaborations, which are key to making a positive impact on healthcare.
With that in mind, Sheba is proud to report the signing of a new partnership with Regeneron, a leading global biotechnology company. Through collaboration, Sheba and Regeneron will advance oncology research to develop new therapeutics for the benefit of patients worldwide.
“We are excited and proud to partner with Regeneron to accelerate clinical research and to enhance patient access to novel treatments,” says Prof. Yitshak Kreiss, Director General of Sheba Medical Center. “This latest agreement exemplifies our mutual desire to improve patient outcomes with an emphasis on creating a better quality of life.”
Led by physician-scientists for nearly 35 years, Regeneron’s unique ability to consistently translate science to clinical practice has led to nine FDA-approved treatments and numerous product candidates in development.
“The Regeneron team is pleased to collaborate with Sheba to accelerate clinical studies of novel oncology therapeutics for patients in need,” stated Dr. David Weinreich, Executive Vice President, Global Clinical Development of Regeneron. “As we work to turn innovative science into vital medicines, we will partner with centers of excellence like Sheba that have established best practice clinical trial processes. We will also share knowledge through programs such as our joint Post-Doctoral Research program, because we know that fighting cancer requires cooperation from the best minds around the world.” While Sheba continually works to improve the-first class medicine and services provided, we never lose sight of what matters – the individual, and are deeply committed to delivering patient-centric, compassionate, and personalized care. As part of this collaboration, Regeneron will partner with the Precision Medicine Hub of Sheba’s ARC (Accelerate, Redesign and Collaborate) Innovation Center, which is devoted to developing advanced, personalized treatments through the use of genomic, proteomic, microbiome, and other data. To that end, Regeneron is also set to join Sheba’s HealthTech Valley, a growing global ecosystem focused on transforming healthcare by bringing together academia, industry, and medicine.
